Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
They're arguing about labeling and post market surveillance; not efficacy.

Thanks Fuma. I guess my worry is that I think labeling can hugely impact how big the market is for the drug. But we don’t know what the FDA’s beef with labeling/postmarketing is and I trust the Experienced CEO.

Regarding my own shares I’m inclined to let them ride. I once owned shares of a drug company who had their PDUFA date postponed by 3 months after the FDA said they needed the extra time due to the drug company supplying additional information regarding the proposed drug’s manufacturing facility.

The unexpected delay produced a +20% overnight drop but shares recovered within weeks.

We’ll see, good luck,
John
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.